David Tirschwell
Neurology · Seattle, WANPI 1851471858
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,420 of the $8,656 with a category attached, or 85.7%. Abbott accounts for 60.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $3,325 and has fallen 71.4% since, to $951 in 2025.
Across 11 payments — averaging $786.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- AbbVie$1K
- Medtronic$1K
- Boston Scientific$820
- Penumbra, Inc.$131
Across 76 payments — averaging $2750.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$115K
- Alnylam Pharmaceuticals Inc.$48K
- Biogen$36K
- Novartis$11K
What the payments were for
- Consulting fees$7,42086%
- Speaking & faculty fees$7509%
- Travel & lodging$2523%
- Food & beverage$2343%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 5 | $5,225 |
| AbbVie | 1 | $1,375 |
| Medtronic(2 entities) | 3 | $1,105 |
| Boston Scientific | 1 | $820 |
| Penumbra, Inc. | 1 | $131 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$3,325
- AMPLATZER Occluders$1,900
- HeartWare HVAD$853
- WATCHMAN FLX$820
- Arctic Front$252
- Artemis$131
How this compares
$8,656 in reported general payments places this provider in the 85th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,859 |
| Levetiracetam | 13 | $235 |
Paid to pharmacies, not to this prescriber.
Other neurology in Seattle
- Pavle RepovicSeattle$1.1M
- Nathaniel WatsonSeattle$486K
- Christyn EdmundsonSeattle$318K
- Pravin KhemaniSeattle$194K
- Mariko KitaSeattle$186K
- Michael RosenbloomSeattle$179K
- Michael WeissSeattle$103K
- Sylvia LucasSeattle$90K
- Shuvro RoySeattle$46K
- Lucas McCarthySeattle$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.